Bern-Thomas Nyang’wa

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis et al. · New England Journal of Medicine · 2022 · 352 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis et al. · The Lancet Respiratory Medicine · 2023 · 96 citations · Full text

Pharmacy, Pharmacotherapy, Antimicrobial Pharmacotherapy +12

Principles for designing future regimens for multidrug-resistant tuberculosis

Grania Brigden, Bern-Thomas Nyang’wa, Philipp du Cros et al. · Bulletin of the World Health Organization · 2013 · 83 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis

Catherine Berry, Philipp du Cros, Katherine Fielding et al. · Trials · 2022 · 66 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +9

Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis

Sedona Sweeney, Catherine Berry, Emil Kazounis et al. · PLOS Global Public Health · 2022 · 35 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17